一种基于无创超声的技术用于识别门静脉高压患者的治疗应答者
本研究基于178例入组患者中21例临床显著门静脉高压(肝静脉压力梯度≥10 mmHg)患者,采用次谐波辅助压力估测(SHAPE)技术每6.2个月复查,评估其监测疾病进展的能力。11例完成随访者中,治疗应答者(n=10)SHAPE信号降低-4.01±3.61 dB,显著大于单一无应答者的2.33 dB(p<0.001),且与MELD评分改善、门静脉高压病因改善、肝功能改善和腹水减少的临床结局一致。作者认为SHAPE可能有助于监测门静脉高压患者的疾病进展,但需更大规模研究进一步验证。
要点
- SHAPE基于超声造影微泡次谐波振幅与环境压力的反比关系估测压力。
- 临床显著门静脉高压定义为肝静脉压力梯度≥10 mmHg。
- 治疗应答者SHAPE信号降低-4.01±3.61 dB,无应答者为2.33 dB(p<0.001)。
关键影像表现/征象
- 治疗应答者(n=10)SHAPE信号降低-4.01±3.61 dB,无应答者(n=1)为2.33 dB,应答者信号降低幅度显著更大(p<0.001)。
- 应答者的SHAPE结果与MELD评分改善、门静脉高压病因改善、肝功能试验改善和腹水减少的临床结局一致。
诊断标准与关键数值
- 临床显著门静脉高压判定标准:肝静脉压力梯度≥10 mmHg。
- 治疗应答判定依据:肝功能试验和临床指标。
临床应用与阅片要点
- 作者认为SHAPE可能监测门静脉高压患者的疾病进展,并可能帮助临床医生进行患者管理。
- 作者指出需更大规模研究进一步验证该结论。
局限性
- 21例门静脉高压受试者中仅11例完成成功随访扫描。
- 无应答者仅1例。
- 作者指出需更大规模研究进一步验证该结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVE: Subharmonic aided pressure estimation (SHAPE) is based on the inverse relationship between the subharmonic amplitude of ultrasound contrast microbubbles and ambient pressure. The aim of this study was to verify if SHAPE can accurately monitor disease progression in patients identified with portal hypertension.
MATERIALS & METHODS: A modified Logiq 9 scanner with a 4C curvi-linear probe (GE, Waukesha, WI) was used to acquire SHAPE data (transmitting and receiving at 2.5 and 1.25 MHz, respectively) using Sonazoid (GE Healthcare, Oslo, Norway; FDA IND 124,465). Twenty-one (median age 59 years; 12 Males) of the 178 patients enrolled in this institutional review board approved study (14F.113) were identified as having clinically significant portal hypertension based on their hepatic venous pressure gradient results ≥ 10 mmHg. Repeat SHAPE examinations were done every 6.2 months. Liver function tests and clinical indicators were used to establish treatment response.
RESULTS: Of the 21 portal hypertensive subjects, 11 had successful follow up scans with an average follow up time of 6.2 months. There was a significantly larger SHAPE signal reduction in the group who were classified as treatment responders (n = 10; -4.01±3.61 dB) compared to the single nonresponder (2.33 dB; p < 0.001). Results for responders matched the corresponding clinical outcomes of improved model for end stage liver disease (MELD) scores, improvement in underlying cause of portal hypertension, improved liver function tests and reduced ascites.
CONCLUSION: SHAPE can potentially monitor disease progression in portal hypertensive patients and hence, may help clinicians in patient management. A larger study would further validate this claim.
引用
- Gupta I, Fenkel JM, Eisenbrey JR, et al. A Noninvasive Ultrasound Based Technique to Identify Treatment Responders in Patients with Portal Hypertension. Acad Radiol. 2020. PMID: 33341374. doi:10.1016/j.acra.2020.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。